Factors influencing pathological complete response to neoadjuvant chemotherapy in resectable breast cancer: A retrospective study

Kang,Jian; Xiong,Huifen; Jiang,Xiaoliu; Huang,Zhaohui; Guo,Yonghong; Cao,Yali; Ding,Jingxian

doi:10.3892/ol.2025.15112

Factors influencing pathological complete response to neoadjuvant chemotherapy in resectable breast cancer: A retrospective study

Authors:
- Jian Kang
- Huifen Xiong
- Xiaoliu Jiang
- Zhaohui Huang
- Yonghong Guo
- Yali Cao
- Jingxian Ding
View Affiliations

Affiliations: Department of Radiation Oncology, The Breast Cancer Institute, Nanchang People's Hospital, Nanchang, Jiangxi 330025, P.R. China, Department of Radiation Oncology, Affiliated Rehabilitation Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Breast Surgery, The Breast Cancer Institute, Nanchang People's Hospital, Nanchang, Jiangxi 330025, P.R. China
Published online on: May 27, 2025 https://doi.org/10.3892/ol.2025.15112
Article Number: 366
Copyright: © Kang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant chemotherapy (NAC) is widely used to treat breast cancer and a pathological complete response (pCR) following NAC is associated with an optimal prognosis; however, pCR rates vary significantly. In the present study, the effects of clinicopathological factors and the administration of different taxanes on pCR rates in patients with resectable breast cancer were assessed. A total of 552 patients with breast cancer who received NAC between May 2019 and June 2024 were included in the present study. The clinicopathological traits of the patients were retrieved from medical records and their association with the pCR rate was evaluated using univariate and multivariate regression analyses. The efficacy of nanoparticle albumin‑bound (Nab)‑paclitaxel, docetaxel and paclitaxel liposomes in different subtypes of breast cancer were further evaluated. A total of 189 of 552 (34.2%) patients achieved pCR following NAC. The pCR rate varied significantly among different molecular subtypes as follows: 58.9% (96/163), 40.7% (37/91), 35.6% (37/104) and 9.8% (19/298) among patients with hormone receptor (HR) negative (‑) human epidermal growth factor receptor 2 (HER2) positive (+), HR⁺HER2⁺, HR^‑HER2^‑ and HR⁺HER2^‑ breast cancer, respectively. The factors estrogen receptor (ER), progesterone receptor and HER2 status, Ki‑67 index and taxane regimen were all significantly associated with pCR in the univariate analysis. In the multivariate regression analysis, ER^‑, HER2⁺, Ki‑67 index ≥30% and Nab‑paclitaxel were independent predictors of pCR. The multivariate regression analysis model had an area under the receiver operating characteristic curve area under the curve of 0.774 (95% confidence interval, 0.735‑0.813). The pCR rates were 41.3, 38.2 and 25.1% among the Nab‑paclitaxel, docetaxel and paclitaxel liposome groups, respectively. Patients with ER^‑, HER2⁺, Ki‑67 index ≥30% were associated with high pCR rates. Moreover, patients who received Nab‑paclitaxel and docetaxel were more likely to achieve pCR compared with paclitaxel liposomes, particularly for those with HER2⁺ and HR‑HER2‑ statuses. In conclusion, molecular subtypes (ER/HER2 status, high Ki‑67) and different taxanes significantly influence pCR likelihood. Nab‑paclitaxel and docetaxel were identified as effective taxanes, highlighting their potential clinical preference, especially in HER2⁺ and HR^‑HER2^‑ breast cancer.

View Figures

View References

1	Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W and He J: Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 4:47–53. 2024. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024. View Article : Google Scholar : PubMed/NCBI
3	Li Y, Song W, Gao P, Guan X, Wang B, Zhang L, Yao Y, Guo Y, Wang Y, Jiang S and Sun S: Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: Findings from the global burden of disease study 2021. BMC Cancer. 25:3302025. View Article : Google Scholar : PubMed/NCBI
4	Freitas AJA, Causin RL, Varuzza MB, Hidalgo Filho CMT, Silva VDD, Souza CP and Marques MMC: Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: Review. Cancers (Basel). 13:54772021. View Article : Google Scholar : PubMed/NCBI
5	Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, Curigliano G, Gentilini O, et al: Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol. 22:e18–e28. 2021. View Article : Google Scholar : PubMed/NCBI
6	Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, et al: Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 19:115–126. 2018. View Article : Google Scholar : PubMed/NCBI
7	Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, et al: Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study. Ann Surg. 276:173–179. 2022. View Article : Google Scholar : PubMed/NCBI
8	von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, et al: Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 31:3623–3630. 2013. View Article : Google Scholar : PubMed/NCBI
9	Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, et al: Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: Systematic review and meta-analysis. BMJ. 375:e0663812021. View Article : Google Scholar : PubMed/NCBI
10	de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 15:1137–1146. 2014. View Article : Google Scholar : PubMed/NCBI
11	Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zheng Q, Yan H, He Y, Wang J, Zhang N, Huo L, Liu Y, Wang L, Xu L and Fan Z: An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation. Cancer. 130:1513–1523. 2024. View Article : Google Scholar : PubMed/NCBI
13	Değerli E, Şentürk Öztaş N, Alkan G, Bedir Ş, Derin S, Valıkhanova N, Saraç B, Kacar E, Demirci NS, Demirelli HF and Turna H: Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. J Chemother. 35:29–38. 2023. View Article : Google Scholar : PubMed/NCBI
14	Zhang T, Liu Y and Tian T: Predicting pathological complete response after neoadjuvant chemotherapy in breast cancer by clinicopathological indicators and ultrasound parameters using a nomogram. Sci Rep. 14:163482024. View Article : Google Scholar : PubMed/NCBI
15	Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 33:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
16	Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, Lee JE and Lee SK: Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. Ann Surg Treat Res. 96:169–176. 2019. View Article : Google Scholar : PubMed/NCBI
17	Maimaitiaili A, Li Y, Chai N, Liu Z, Ling R, Zhao Y, Yang H, Liu Y, Liu K, Zhang J, et al: A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: A nationwide, multicenter retrospective cohort study (CSBrS-012). Front Oncol. 14:13263852024. View Article : Google Scholar : PubMed/NCBI
18	Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 401:1277–1292. 2023. View Article : Google Scholar : PubMed/NCBI
19	Nižnanský Ľ, Osinová D, Kuruc R, Hengerics Szabó A, Szórádová A, Masár M and Nižnanská Ž: Natural taxanes: From plant composition to human pharmacology and toxicity. Int J Mol Sci. 23:156192022. View Article : Google Scholar : PubMed/NCBI
20	Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, et al: Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 22:331–357. 2024. View Article : Google Scholar : PubMed/NCBI
21	Symons R, Heath F, Duggan J, Bui KT, Byun L, Friedlander M and Lee YC: Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis. Support Care Cancer. 32:2922024. View Article : Google Scholar : PubMed/NCBI
22	Bi Z, Chen P, Liu YB, Zhao T, Sun X, Song XR and Wang YS: Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer. Breast Cancer Res Treat. 184:397–405. 2020. View Article : Google Scholar : PubMed/NCBI
23	Dieci MV, Griguolo G, Bottosso M, Tsvetkova V, Giorgi CA, Vernaci G, Michieletto S, Angelini S, Marchet A, Tasca G, et al: Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer. 7:1012021. View Article : Google Scholar : PubMed/NCBI
24	Giuliano AE, Edge SB and Hortobagyi GN: Eighth Edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 25:1783–1785. 2018. View Article : Google Scholar : PubMed/NCBI
25	Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, Darby SC and Taylor CW: Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev. 105:1023752022. View Article : Google Scholar : PubMed/NCBI
26	Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, et al: Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive Meta-analysis. Clin Cancer Res. 26:2838–2848. 2020. View Article : Google Scholar : PubMed/NCBI
27	Ortmann O, Blohmer JU, Sibert NT, Brucker S, Janni W, Wöckel A, Scharl A, Dieng S, Ferencz J, Inwald EC, et al: Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: Analysis of individual data from 94,638 patients treated in 55 breast cancer centers. J Cancer Res Clin Oncol. 149:1195–1209. 2023. View Article : Google Scholar : PubMed/NCBI
28	Guan D, Jie Q, Wu Y, Xu Y, Hong W and Meng X: Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: A multicenter, retrospective study in China. World J Surg Oncol. 20:3262022. View Article : Google Scholar : PubMed/NCBI
29	Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer HU, Fasching PA, Weber KE, et al: Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors-An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer. 148:159–170. 2021. View Article : Google Scholar : PubMed/NCBI
30	Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
31	Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, et al: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. Lancet Oncol. 19:497–509. 2018. View Article : Google Scholar : PubMed/NCBI
32	Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, et al: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6:676–684. 2020. View Article : Google Scholar : PubMed/NCBI
33	Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al: Pembrolizumab for early Triple-negative breast cancer. N Engl J Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
34	Dou H, Li F, Wang Y, Chen X, Yu P, Jia S, Ba Y, Luo D, Gao T, Li Z and Xiao M: Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy. Diagn Pathol. 19:52024. View Article : Google Scholar : PubMed/NCBI
35	Ahn S, Woo JW, Lee K and Park SY: HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 54:34–44. 2020. View Article : Google Scholar : PubMed/NCBI
36	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014. View Article : Google Scholar : PubMed/NCBI
37	Baumgartner A, Tausch C, Hosch S, Papassotiropoulos B, Varga Z, Rageth C and Baege A: Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast. 39:19–23. 2018. View Article : Google Scholar : PubMed/NCBI
38	Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, et al: Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 24:2786–2793. 2013. View Article : Google Scholar : PubMed/NCBI
39	Kim SY, Cho N, Choi Y, Lee SH, Ha SM, Kim ES, Chang JM and Moon WK: Factors affecting pathologic complete response following neoadjuvant chemotherapy in breast cancer: Development and validation of a predictive nomogram. Radiology. 299:290–300. 2021. View Article : Google Scholar : PubMed/NCBI
40	Li Y, Chen X, Zhu Q, Chen R, Xu L, Li S, Shi X, Xu H, Xu Y, Zhang W, et al: Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer. Nanomedicine (Lond). 16:391–400. 2021. View Article : Google Scholar : PubMed/NCBI
41	Wu X, Ye C, Wang X, Cai R, Yang J, Yu X, Zhou Y, Shen L, Zhu Y and Liu X: The efficacy and toxicity of neoadjuvant chemotherapy regimens of epirubicin plus cyclophosphamide followed by docetaxel or paclitaxel in female breast cancer patients. Cancer Manag Res. 13:1517–1527. 2021. View Article : Google Scholar : PubMed/NCBI
42	Jivani A and Shinde RK: A comprehensive review of taxane treatment in breast cancer: Clinical perspectives and toxicity profiles. Cureus. 16:e592662024.PubMed/NCBI
43	Zhang W, Wang Y, He J, Xu Y, Chen R, Wan X, Shi W, Huang X, Xu L, Wang J and Zha X: Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer. Nanomedicine. 54:1027072023. View Article : Google Scholar : PubMed/NCBI
44	Zhang W, Xu Y, Shi X, Huang X, Chen R, Xu H, Shi W, Wan X, Wang Y, He J, et al: Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer. Nanomedicine (Lond). 17:683–694. 2022. View Article : Google Scholar : PubMed/NCBI